Document Detail


Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin.
MedLine Citation:
PMID:  15855754     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The treatment of small intestine bacterial overgrowth should address different aims: the removal of the predisposing condition, guarantee of adequate nutritional support to reintegrate both caloric and vitamin requirements and, obviously, suppression of the contaminating bacterial flora, which represents the major goal. The polymicrobic nature of contaminating flora suggests the administration of wide-spectrum antibiotics, but until now there has been no conclusive information on the most effective therapeutic approach. In this paper, the efficacy of the different therapeutic approaches used is reviewed.
Authors:
Michele Di Stefano; Gino Roberto Corazza
Related Documents :
15113174 - Antioxidant activity of processed table beets (beta vulgaris var, conditiva) and green ...
20388054 - Micronutrients and women of reproductive potential: required dietary intake and consequ...
9808224 - Reappraisal of the role of vegetables in the vitamin a status of mothers in central jav...
16958314 - What is an adequate dose of oral vitamin b12 in older people with poor vitamin b12 status?
1396474 - A new simplified dietary history method for measuring intake of energy and macronutrients.
23420574 - Potent inhibitory effect of alcoholic beverages upon gastrointestinal passage of food a...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Chemotherapy     Volume:  51 Suppl 1     ISSN:  0009-3157     ISO Abbreviation:  Chemotherapy     Publication Date:  2005  
Date Detail:
Created Date:  2005-04-27     Completed Date:  2005-07-15     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0144731     Medline TA:  Chemotherapy     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  103-9     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2005 S. Karger AG, Basel.
Affiliation:
Gastroenterology Unit, IRCCS S. Matteo Hospital, University of Pavia, Pavia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Bacterial Agents / therapeutic use*
Bacteria / drug effects*,  growth & development
Bacterial Infections / drug therapy*
Clinical Trials as Topic
Dietary Supplements
Gastrointestinal Agents / therapeutic use
Humans
Intestinal Absorption
Intestinal Diseases / drug therapy*
Intestine, Small / microbiology*
Rifamycins / therapeutic use*
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Gastrointestinal Agents; 0/Rifamycins; 88747-56-2/rifaximin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Management of inflammatory bowel disease: does rifaximin offer any promise?
Next Document:  Management of diverticular disease: is there room for rifaximin?